We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The early trial tested the RNA-based drug, QR-110, in 10 patients with a certain genetic mutation that resulted in an eye disorder called Leber’s congenital amaurosis 10